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Abstract
An abrupt increase in metastatic growth as a consequence of the removal of primary tumors suggests that the
concomitant resistance (CR) phenomenon might occur in human cancer. CR occurs in murine tumors and ROS-
damaged phenylalanine, meta-tyrosine (m-Tyr), was proposed as the serum anti-tumor factor primarily responsible for
CR. Herein, we demonstrate for the first time that CR happens in different experimental human solid tumors (prostate,
lung anaplastic, and nasopharyngeal carcinoma). Moreover, m-Tyr was detected in the serum of mice bearing prostate
cancer (PCa) xenografts. Primary tumor growth was inhibited in animals injected with m-Tyr. Further, the CR
phenomenon was reversed when secondary implants were injected into mice with phenylalanine (Phe), a protective
amino acid highly present in primary tumors. PCa cells exposed to m-Tyr in vitro showed reduced cell viability,
downregulated NFκB/STAT3/Notch axis, and induced autophagy; effects reversed by Phe. Strikingly, m-Tyr
administration also impaired both, spontaneous metastasis derived from murine mammary carcinomas (4T1, C7HI, and
LMM3) and PCa experimental metastases. Altogether, our findings propose m-Tyr delivery as a novel approach to
boost the therapeutic efficacy of the current treatment for metastasis preventing the escape from tumor dormancy.
Introduction
Concomitant tumor resistance (CR) is the phenomenon
in which a tumor-bearing host inhibits the growth of
secondary tumor implants. Ehrlich1 first described it in
1906, but this phenomenon remained forgotten for about
60 years. After its renascence, it was demonstrated that
both immunogenic and non-immunogenic tumors could
induce CR in different animal models2. CR may be rele-
vant to understand putative mechanisms of metastases
control on the basis that metastases could be considered
as secondary tumor implants developed spontaneously
during the primary tumor growth3. Management of
metastasis continues to be the Achiles’ heel of cancer4,
since in many types of cancers, patients’ tumor relapse
and often the responses produced to the adjuvant therapy
are palliative and unpredictable.
Different explanations were proposed to address CR.
The immunological hypothesis detailed how the growth
of a tumor triggered an anti-tumor immune response, not
strong enough to impair the growth of the primary tumor,
but capable of suppressing the development of the sec-
ondary tumor inoculum5. However, the CR phenomenon
was also observed in the absence of an immune reac-
tion6,7. Non-immunological explanations included atrep-
sis1. However, others implied that the production and
secretion of anti-proliferative or anti-angiogenic
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molecules by the primary tumor, limited the replication
potency of tumor cells at secondary sites6.
In previous papers, using murine tumors widely differ-
ent in origin, histology, and immunogenicity, we
demonstrated that two temporally separate events of CR
are detected during primary tumor growth7,8. The first
event was only induced by small (≤500 mm3) immuno-
genic tumors, it was tumor-specific and thymus-depen-
dent, and a typical immunological rejection was observed
histologically at the site of the second tumor implant
undergoing CR. The second event of CR was mediated by
most large-sized (≥2000mm3) immunogenic and non-
immunogenic tumors and its intensity was proportional
to tumor mass. In addition, the second event of CR was
tumor-non-specific, thymus-independent, and it was
unassociated with well-characterized growth-inhibitory
molecules such as interferons, tumor necrosis factor-α,
transforming growth factor (TGF)-β, angiostatin, and so
on6,8, but with the serum factor(s) meta-tyrosine (m-Tyr)
and ortho-tyrosine (o-Tyr)9, two isomers of tyrosine not
present in normal proteins, m-Tyr and o-Tyr were
responsible for 90% and 10%, respectively, of the total
serum anti-tumor activity, as demonstrated by in vitro
and in vivo experiments on the growth of three different
murine tumors that induce CR and on a fourth tumor that
does not induce CR, suggesting that m-Tyr can inhibit the
proliferation of both types of tumors10. An excess of para-
tyrosine (p-Tyr), the natural occurring isomer of tyr-
osine10, could not counteract the effect of m-Tyr and o-
Tyr. In contrast, phenylalanine (Phe) reverted the inhibi-
tory effects produced by both tyrosine isomers in a dose-
dependent manner10.
In this work, we demonstrated for the first time that the
phenomenon of CR may be induced by different
experimental human solid tumors (prostate, lung anaplastic,
and nasopharyngeal carcinoma) growing in immune-
deficient nude mice and that the kinetics of this CR paral-
leled the second event of CR induced by murine tumors. We
also show that m-Tyr mediates CR induced by human
tumors (using the prostate PC3 line as model) and identify
the signaling pathways involved. Moreover, we demon-
strated that m-Tyr administration impairs spontaneous and
experimental metastasis derived from murine and human
tumors, mammary carcinomas (4T1, C7HI, and LMM3),
and PCa experimental metastases, ascertaining it as a
potential therapeutic factor for cancer metastasis.
Results
Concomitant resistance occurs in experimental human
xenografts
To determine whether CR was occurring in human
xenografts, we analyzed different solid tumor experi-
mental models. Male nu/nu mice of 8–10 weeks old were
randomized into two groups. Human PCa cells were
injected s.c. in the right flank of the experimental group
(primary tumor-bearing mice) and, at selected times (7,
14, or 21 days) after tumor inoculation—when PC tumor
volumes were 101± 17, 317± 42, or 752± 114mm3
(mean ± S.E.M.), respectively—a secondary tumor
implant was carried out in the left flank. Control mice
only received the tumor implant in the left flank (Fig. 1a).
Body weight and tumor growth were measured every
2 days starting at 8 days after inoculation when tumors
became palpable under the skin. The growth of the sec-
ondary tumor implants was significantly inhibited in the
experimental group and the intensity of this inhibition
was proportional to the primary tumor volume at the time
of the secondary tumor implant: the larger the primary
Fig. 1 Concomitant resistance occurs in PCa. a Schematic representation of CR strategy. b Male athymic (nu/nu) mice of 6–8 weeks old were
randomized into four groups: control (n = 5) and three experimental groups (small, medium, and large primary tumors (n = 5)). Tumor cells (5 × 106)
were s.c. injected in the right flank at −21, −14, and −7 days of the experimental groups (primary tumors). At day 0, a second inoculation (3 × 106
tumor cells) was performed in the left flank of the control and experimental groups (secondary tumors). Body weight and tumor growth were
measured every 2 days starting at 7 days after inoculation when the tumors became detectable under the skin. One representative from at least three
independent experiments is shown. The graph shows the average tumor volumes ± S.E.M. *P < 0.05, ***P < 0.001
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tumor volume, the stronger the inhibition of the sec-
ondary tumor implant (Fig. 1b).
We extended our findings and confirmed the CR phe-
nomenon in two other experimental human solid tumor
models, Calu6 (lung anaplastic carcinoma)11 and KB
(nasopharyngeal carcinoma)12,13. As occurred with the PC
model, Calu-6 and KB tumors clearly showed a significant
reduction in the growth of the secondary implants that was
proportional to the primary tumor volume at the time of the
secondary tumor implant (Supplementary Fig. 1).
Anti-proliferative activity of serum from mice bearing
subcutaneous prostate tumors
To test whether the serum from mice bearing sub-
cutaneous prostate tumors had anti-tumoral activity, PC3
cultures were exposed to twofold serum dilutions 1:4 and 1:8
for 18 h, and [3H]-thymidine incorporation was measured.
The titer of the growth-inhibitory activity was defined as the
reciprocal of the serum dilution producing 50% inhibition of
[3H]-thymidine uptake by tumor cells as compared to con-
trols (GIU50 per ml). Serum was obtained from animals
bearing either a large tumor (1875mm3) or a small tumor
(400mm3). Results showed a significant increase in the
GIU50 per ml for both sera compared with controls, with
significantly higher anti-proliferative activity for serum from
mice bearing large prostate tumors (Fig. 2a). Accordingly,
serum from animals with small (100mm3) and large Calu6
tumor (1700mm3) presented an elevated GIU50 per ml
compared to controls (Supplementary Fig. 2). These results
suggested a direct correlation between the anti-tumor
activity found in serum and the intensity of CR produced
by each tumor at different stages of tumor growth.
Identification of m-Tyr and o-Tyr in the serum of mice
bearing PCa xenografts
Next, sera from mice bearing subcutaneous prostate
tumors were purified and analyzed. p-Tyr, m-Tyr, and
o-Tyr were identified by high-performance liquid
chromatography (HPLC)-ultraviolet (UV) methodology10.
The mobile phase consisted of a mixture of water:methanol:
trifluoroacetic (87:12:1), the flow rate was set at 0.5ml per
min, and the UV detection was performed at 280 nm
(Fig. 2b). Standards for p-Tyr, m-Tyr, and o-Tyr were used
for validation (Fig. 2c). Results confirmed the presence p-
Tyr, m-Tyr, and o-Tyr in control and experimental samples
with a significant increase of the three metabolites in sera
from mice bearing subcutaneous prostate tumors (Fig. 2c).
m-Tyr treatment mimics concomitant resistance occurring
in human xenografts
Given that m-Tyr anti-tumor power proved to be 10
times more robust than that of o-Tyr10, we furthered our
studies using this agent in PCa models. We assessed
whether m-Tyr could mimic CR occurring in human PCa
and that Phe could reverse this effect. Animals were
randomly assigned into four groups: control; experimental
(CR); Phe and m-Tyr. PC3 cells were s.c. inoculated (first
challenge) in the right flank of animals of the CR and Phe
groups. A second challenge was performed 14 days later
in the left flank of the animals of all groups (Fig. 3a) and
24 h later, Phe and m-Tyr groups received the respective
amino acids in the same site for 16 consecutive days
(Fig. 3a). The RC phenomenon was recapitulated as the
one observed in Fig. 1 (83.88% tumor volume decrease,
**P< 0.01). m-Tyr group displayed significant tumor
volume decrease compared to the control group by an
average of 78.33% (**P< 0.01). Interestingly, Phe group
presented a significant increase in tumor volume com-
pared to the CR group (5.7 fold induction, **P< 0.01),
further evidencing the counteraction of Phe on the CR
phenomenon (Fig. 3b).
m-Tyr treatment inhibits experimental and spontaneous
metastasis
Human tumors do not produce spontaneous metastases
when growing into nu/nu mice. For this reason, m-Tyr
effect was tested in a model of experimental PCa metas-
tasis. Nude mice were i.v. challenged with PC3 tumor cells
and starting 1 day later (when metastases were not yet
established) or 14 days later (when metastases were
already established in lung), mice were injected with
m-Tyr (treated groups) or saline (control groups) on a
daily basis for the following 21 days (Fig. 4a, d). At days 21
or 34 after tumor inoculation, animals were killed and
evaluated for pulmonary metastases (Fig. 4b, e). m-Tyr
treatment drastically decreased the number of lung
metastases as compared to controls. The Kaplan–Meier
overall survival curves show the significant difference in
the percentage of survivors for m-Tyr-treated and control
mice as a function of the days after tumor cell injection
(Fig. 4c, f).
We extended our studies to assess the inhibitory effect
of m-Tyr on spontaneous metastasis. Using metastatic
murine mammary carcinomas 4T1, C7HI, and LMM3, we
analyzed the dose–response of m-Tyr administration.
BALB/c mice were s.c. injected with the different carci-
noma cells and when tumor volume reached 400mm3
mice received either m-Tyr or saline for the following 20
consecutive days. An additional group was killed at the
onset of treatment to evaluate the basal number of
metastases. The rest of the groups were subsequently
euthanized and lung and hepatic metastases were counted
(Fig. 5a–c, Supplementary Fig. 3). Figure 5b depicts
representative hemotoxylin and eosin (H&E) staining of
pulmonary and draining lymph node metastasis of mice
bearing s.c. LMM3 tumors. A significant reduction in the
number of lung metastases by m-Tyr treatment was
detected for the three experimental models (Fig. 5c).
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Further, we assessed the m-Tyr effect on the survival of
LMM3-excised mice exhibiting established lung metas-
tases at the time of surgery. BALB/c mice were s.c.
inoculated with LMM3 tumor cells. Twenty-five days
later, tumor-bearing mice were operated to remove the
tumor and the remaining mice, were killed to evaluate the
number of lung metastases at the time of surgery (mean
(range)= 18 (12–25)). Next, tumor-excised mice received
daily i.v. either m-Tyr or saline for the following 35
consecutive days (Fig. 5e). No tumor relapse at the site of
inoculation was seen after surgical excision. The
Kaplan–Meier estimator of the overall survival curves
evidenced a significant difference in the percentage of
survivors for m-Tyr-treated vs. control mice as a function
of time after tumor excision (Fig. 5f). While all control
mice died exhibiting a high number of lung metastases at
36.9± 6.7 days (mean± S.E.M.) after surgery, in contrast,
50% of mice died in the m-Tyr group, while the other 50%
remained alive without exhibiting signs of local or meta-
static disease in the long run (Fig. 5f). Further, when these
mice were killed 18 months after the end of the treatment,
no metastatic foci were detected.
The analysis of potential toxic side effects associated
with m-Tyr periodic administration (45 days) revealed
neither histologic nor cytologic alterations, even when
organs with high rate of renewal (skin, bone marrow, or
small intestine) were studied (Supplementary Fig. 4).
Leukocyte subsets in both draining lymph nodes and the
Fig. 3 m-Tyr treatment mimics concomitant resistance in human xenografts. a Counteracting effect of phenylalanine (Phe) on tumor growth
inhibition induced by CR and inhibitory effect of m-Tyr on in vivo tumor growth mimicking the inhibition induced by CR. b The animals were
randomly assigned into four groups: control; CR; Phe and m-Tyr. PC3 cells (5 × 106) were s.c. inoculated in the right flank of animals of the CR and Phe
groups. A total of 3 × 106 cells were inoculated in the left flank of the animals of all groups 14 days after the first challenge. Both, Phe and m-Tyr
groups were injected, in the left flank at the site of the tumor implant with Phe or m-Tyr (0.2 ml of 500 mg/ml, n = 10) respectively, for 15 days on a
daily basis. Tumor growth was measured every 2 days starting 8 days after inoculation when the tumors were palpable. The graph shows the average
tumor volumes of left flank implants ± S.E.M. One representative from at least five independent experiments is shown. **P < 0.01
(see figure on previous page)
Fig. 2 Anti-proliferative activity of serum from mice bearing subcutaneous prostate tumors. a PC3 cells (3 × 105) were exposed to twofold
serum dilutions 1:4 and 1:8 (24 h), and 1 mCi/ml of [3H]-thymidine. Radioactivity incorporated into the cells was determined in a β-counter
(Beckman). The titer of growth-inhibitory activity was defined as the reciprocal of the serum dilution producing 50% inhibition of [3H]-thymidine
uptake by tumor cells as compared with [3H]-thymidine uptake by tumor cells cultured in medium only (GIU50 per ml). Results show the mean ± S.E.
M of three samples of normal serum, three samples of serum from mice bearing large PC3 tumors (1700 mm3 approximately), and three samples of
serum from mice bearing small PC3 tumors (500 mm3 approximately). Each dilution of each serum was assayed in triplicate. *P < 0.05; ***P <
0.001 significant difference. b Strategy of p-tyrosine (p-Tyr), m-Tyrosine (m- Tyr), and o-tyrosine (o-Tyr) purification from PC3 tumor-bearing and
control mice serum. c p-tyrosine (p-Tyr), m-Tyrosine (m- Tyr), and o-tyrosine (o-Tyr) determinations were carried out using an HPLC-UV methodology
previously developed (Ruggiero et al.10). Briefly the separation of p-Tyr, m-Tyr, and o-Tyr was performed in a C-18 Zorbax column (Agilent, 7.5 mm ×
4.6 mm i.d., 5 μm particle size). The mobile phase consisted in a mixture of water:methanol:trifluoroacetic (87:12:1), the flow rate was set at 0.5 ml per
min and the UV detection was performed at 280 nm. The right panel shows the retention times for p-Tyr, m-Tyr, and o-Tyr standards used for
validation. One representative from at least three independent experiments is shown. SS saline solution
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spleen were not altered (Supplementary Fig. 4). Accord-
ingly, m-Tyr-treated mice did not display significant
changes in either the humoral or the cellular immune
responses, observed by the titer of sheep red blood cell-
specific antibodies and delayed hypersensitivity against
ovoalbumin, respectively, and did not exhibit any other
detectable functional alterations assessed by the number
of erythrocytes, leukocytes, and platelets in the blood and
the concentration of circulating hepatic GOT and GPT
transaminases, total proteins, urea, creatinine, alkaline
phosphatase, cholesterol, and glucose.
In vitro effect of m-Tyr
To explore m-Tyr cellular effects in vitro, we assessed
m-Tyr and/or Phe (100 and 150 μg/ml) effect on cell
growth and cell cycle progression in the PCa cell line,
PC3. m-Tyr significantly reduced cell viability in a dose-
dependent manner, effect that was completely reversed by
the addition of Phe in equivalent concentrations. Phe
alone had no effect on PC3 cell viability (Fig. 6a). Addi-
tionally, m-Tyr (150 μg/ml) produced a significant arrest
of PC3 cells in G0/G1 phase (Fig. 6b). This increase in G0/
G1 cell population was mostly at the expense of the S
phase. Accordingly, this effect was counteracted by the
addition of Phe in equivalent concentrations. Phe alone
had no effect on the distribution of the cell cycle popu-
lation (Fig. 6b).
To assess m-Tyr cellular effects at the molecular level,
we evaluated NFκB activity. NFκB is constitutively acti-
vated in human PCa and correlates with disease pro-
gression14. Using a reporter construct containing five
repeats of the NF-KB consensus binding sequence cloned
upstream of the luciferase gene (pNFκB-luc), we showed
that m-Tyr significantly repressed (45.14%, *P< 0.05) the
transcriptional activity of the NFκB-luc in PC3 cells
(Fig. 6c). Phe addition partially reversed the inhibition
produced by m-Tyr but no alterations were observed in
the reporter activity by Phe alone (Fig. 6c). For control
purposes, we transfected PC3 cells with the mutated
inhibitor IkBss confirming the NFκB transactivation
inhibition (78.24%, *P< 0.05, Fig. 6c).
Given the tight association between STAT3 and PCa
and that NFκB and STAT3 are two oncogenic
transcriptional factors activated simultaneously and
cooperatively inducing various survival factors15, we next
evaluated the effect of m-Tyr and Phe on STAT3 activa-
tion. As the role of STAT3 as a DNA-binding transcrip-
tion factor depends on its ability to gain entrance to the
nucleus, STAT3 cellular localization in PC3 cells treated
with m-Tyr were imaged by confocal microscopy. The
images displayed in Fig. 5d showed that m-Tyr reduced
STAT3 expression and nuclear localization. Phe addition
partially restored both parameters (Fig. 6d). By reverse
transcription quantitative polymerase chain reaction (RT-
qPCR), we assessed survivin expression (downstream
target of STAT3) and confirmed its downregulation by m-
Tyr (Fig. 6e). Further we also detected significantly low-
ered MKI67 mRNA levels in m-Tyr-treated PC3 cells
compared to controls (Fig. 6e).
The constitutive activation of STAT3/NFκB signaling
can regulate the Notch pathway, which appears to play a
key role in a variety of cancers and controls cell fate
determination, survival, proliferation, and the main-
tenance of stem cells16–18. Hence, we also screened for
molecular targets associated with the Notch pathway.
Results showed a significant downregulation of HES1
mRNA levels (44.6%, *P< 0.05) when cells were exposed
to m-Tyr (Fig. 6e).
Previous reports show that STAT3 inhibition induces
signs of autophagy19. Moreover, m-Tyr (ROS-damaged
phenylalanine) may be incorporated into eukaryotic pro-
teins via a specific tRNA-dependent pathway, using
mitochondrial and possibly cytosolic phenylalanyl-tRNA
synthetase20 and elevated m-Tyr content in proteins may
lead to the dysfunction of intracellular signaling and
activation of autophagy. To identify m-Tyr as a novel
inducer of autophagy in PCa, we assessed LC3 lipidation
indicated by the conversion of LC3-I into LC3-II. Results
show that endogenous levels of LC3-II accumulated upon
m-Tyr treatment (Fig. 6f). This effect was counteracted by
the addition of Phe. No detectable levels of LC3-II were
observed for Phe treatment alone (Fig. 6f). We also
examined if autophagosomes were fusing with lysosomes
into autophagolysosomes under m-Tyr, adding bafilomy-
cin A1 (BafA1)21. Results showed LC3-II accumulation
upon exposure of cells to m-Tyr in the presence of BafA1,
(see figure on previous page)
Fig. 4 m-Tyr inhibits experimental metastasis of PCa. a, d Schematic representation of the in vivo assay carried out to assess the role of m-Tyr in
PCa experimental metastasis. Nude mice (n = 19) were i.v. challenged with 2 × 106 PC3 tumor cells, and were subsequently injected withm-Tyr (n = 9)
or saline (n = 10) on a daily basis (i.v. administration; 67 mg/kg/day). Animals were killed 20–25 days after tumor cell inoculation and evaluated for
pulmonary metastases. b Pulmonary metastases were counted under a dissecting microscope. c Percent survival of nude mice (n = 10) inoculated
with 2 × 106 PC3 tumor cells i.v. (day 0). The figure shows the percentage of the survivors of m-Tyr-treated and control mice (saline solution i.v.
administration) as a function of the days after tumoral cells injection. d Schematic representation of PCa experimental metastasis delivering m-Tyr
14 days post tumor cell inoculation, when metastases were already established in lung. e Pulmonary metastases were counted under a dissecting
microscope. f Percentage of survivors of m-Tyr-treated and control mice (saline solution i.v. administration) as a function of the days after tumoral
cells injection (2 × 106 PC3 cells). *P < 0.05, **P < 0.01, *** P < 0.001 significant difference
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Fig. 5 m-Tyr inhibits spontaneous metastasis. a Schematic representation of the in vivo assay carried out to assess the role of m-Tyr in
spontaneous metastasis using three metastatic murine mammary carcinomas C7HI, LMM3, and 4T1. For C7HI tumors, BALB/c mice were s.c. injected
with 2 × 105 cells and 40 days later animals received a daily i.v. injection of m-Tyr (67 mg/kg/day) or saline for the following 20 consecutive days. A
third group was killed at day 40 to evaluate the number of metastases at the onset of treatment (basal). At day 60, all treated and control mice were
killed and metastases counted. For LMM3 tumors and 4T1 tumors, BALB/c mice were s.c. injected with 2 × 105 cells and 25 days later animals received
a daily i.v. injection of m-Tyr or saline as previously described. A third group was killed at day 25 to evaluate the number of metastases at the onset of
treatment (basal). At day 45, all treated and control mice were EUTHANIZE and metastases counted. All experiments were done in triplicates. b
Representative H&E staining of pulmonary and draining lymph nodes metastasis of mice bearing s.c. LMM3 tumors (×25, Scale bar = 100 μm). Arrows
point sites of tumor cells in the same field. c Pulmonary C7HI, LMM3, or 4T1 metastases form-Tyr treatment. d Schematic representation of the in vivo
assay carried out to assess the role of m-Tyr effect on the survival of LMM3-excised mice exhibiting established lung metastases at the time of
surgery. BALB/c mice were s.c. inoculated with 2 × 105 LMM3 tumor cells. Twenty-five days later, tumor-bearing mice were surgically operated to
remove the tumor and the remaining mice were killed to evaluate the number of lung metastases at the time of surgery. Tumor-excised mice were
divided into two groups: m-Tyr (daily i.v. injection of m-Tyr, 67 mg/kg, for consecutive 35 days) and control group (daily i.v. injection of saline for
consecutive 35 days). e Kaplan–Meier estimator for survival indicating the percentage of survivors for m-Tyr-treated vs. control mice as a function of
the days after tumor excision. *P < 0.05, **P < 0.01, ***P < 0.001
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strongly suggesting that m-Tyr induced autophagosome
formation and that the autophagic pathway was functional
(Fig. 6f).
Discussion
Surgical removal is one of the main treatments for solid
tumors. However, although it is recommended in most
clinical cases, tumor removal may trigger the acceleration
of regional and distant metastases. This suggests that the
primary tumor could inhibit the growth of its own
metastases, an event that is mimicked by the phenomenon
of CR induced in experimental animal models9.
Michelson and Leith22 attempted to provide mathe-
matical modeling explanation rather than a biological one
to address the occurrence of CR. However, these authors
failed to elucidate the central paradox of CR, that is, the
inhibition of secondary tumor implants together with the
progressive growth of the primary tumor, because in their
mathematical constructs, they did not offer a plausible
explanation for the fact that inhibitory factors produced
by the primary tumor could not affect it.
Here, we propose a novel therapeutic option for meta-
static tumors. We discovered that m-Tyr treatment sig-
nificantly abolished the proliferative capacity of cancer
cells and further impaired tumor growth when cells were
xenotransplanted in nu/nu in experimental human cancer
models. Accordingly, Phe, a protective amino acid highly
present in primary tumors and precursor of m-Tyr, was
capable of reversing the effects caused by m-Tyr.
Gurer-orhan et al.23 reported m-Tyr incorporation into
proteins by CHO (Chinese-hamster ovary) cells and that it
impaired CHO cell viability. They suggested that this m-
Tyr might be misincorporated into proteins during
translation and that this mechanism could contribute to
its toxicity. Further m-Tyr has been reported as a potent,
structurally unusual broad-spectrum phytotoxin exuded
by the roots of some fine leaf fescue grasses that allow
them to outcompete or displace neighboring plants24.
The specific pathway by which ROS-damaged amino
acids are incorporated into proteins remains unclear.
However, Klipcan et al.25 provided evidence that
phenylalanyl-tRNA synthetases (PheRS) catalyze the
direct attachment of m-Tyr to tRNAPhe, delivering
the misacylated tRNA to the ribosome and enabling the
incorporation of the ROS-damaged amino acid into
eukaryotic proteins. Crystal complexes of PheRSs with
m-Tyr describe the net of highly specific interactions
within the synthetic and editing sites.
Accumulation of damaged proteins evidences the
inefficient proteolytic machinery. This is commonly seen
by the increased amounts of aggregated, misfolded, and
oxidized proteins that accumulate in atherosclerosis,
neurodegeneration, and cancer. Mildly oxidized proteins
are usually degraded by the proteasome system26.
However, in the case of abundant oxidized proteins,
there are evidences pointing to the autophagy of such
proteins27.
Our results showcase m-Tyr as a novel inducer of
autophagy in PCa. PC3 cells exposed to m-Tyr display
accumulated levels of LC3-II, effect counteracted by the
addition of Phe. Further, the addition of BafA1 confirmed
the autophagosome formation by m-Tyr and the func-
tionality of the autophagic pathway. The autophagic sce-
nario in carcinogenesis, metastasis, and cancer therapy is
highly complex with reports demonstrating functions in
tumor promotion as well as in tumor suppression and a
potential contribution to therapeutic resistance28. More-
over, the high level of heterogeneity within a tumor adds a
greater degree of complexity to whether this cellular
mechanism may favor or not tumor dormancy29.
(see figure on previous page)
Fig. 6 In vitro m-Tyr downregulates key signaling pathways in PCa. a PC3 cell survival was assessed by the colorimetric MTS assay. Cells were
cultured in the presence of m-Tyr (100l or 150 μg/ml; 24 h) and/or Phe (100 or 150 μg/ml; 24 h). Results are expressed as the viability percentage
relative to the control in the presence of the vehicle (100%) ± S.E.M. (*P < 0.05, significant difference). b Effect of m-Tyr (150 μg/ml; 24 h) and/or Phe
(150 μg/ml; 24 h) on cell cycle progression in PC3 cells. Once treated, cells were processed for DNA staining with propidium iodide. Flow cytometry
analysis was performed for cell cycle distribution. The percentage of cells in different phases of cell cycle was determined by ModFit LT cell cycle
analysis software (left panel). The right panel shows the percentage relative to control of cells in each population. Data shows the mean of five
independent experiments ± S.D.. c PC3 cells were transfected with a NFκB—responsive luciferase reporter construct and were exposed to m-Tyr
(150 μg/ml, 24 h) and/or Phe (150 μg/ml, 24 h). Ikbss was used as a negative control. d PC3 cells were cultured in the presence of m-Tyr (150 μg/ml;
24 h), m-Tyr + Phe (150 μg/ml; 24 h) or vehicle. Cells were fixed and stained with anti-STAT3 primary antibody and a secondary antibody conjugated
to Alexa Fluor 488. Segmentation of the whole cell and nucleus (DAPI) was performed to calculate the ratio of STAT3n/STAT3t in a cell-by-cell analysis
and the florescence intensity for STAT3 was calculated using Matlab and normalized to the cell size (n≥ 20 cells for each condition). (*P < 0.05,
significant difference). e PC3 cells were pre-treated with different concentrations ofm-Tyr (150 μg/ml; 24 h) or control (Ctrol). Total RNA was extracted
and the expression levels of mRNA for each gene, were determined by RT-qPCR. Data were normalized to cyclophilin-A. One representative from
at least three independent experiments is shown. f Autophagy levels in response to m-Tyr. PC3 cells were treated with m-Tyr (150 μg/ml), Phe
(150 μg/ml) or (m-Tyr/ Phe 150 μg/ml) for 24 h. Cells were treated with Bafilomycin A1 (BafA1 100 nM) 2 h before collecting. Treatment with
rapamycin was used as a positive control (1 μ for 6 h). Western blot was performed with specific antibodies against for LC3I and LC3II (left panel).
Densitometry analysis was performed (right panel). *P < 0.05, **P < 0.01 significant difference
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Next, we explored m-Tyr impact on the STAT3/NFκB/
Notch signaling cascade. This axis is activated in several
tumor types30, and is also associated with the autophagy
process and of particular relevance in PCa16–18. Our data
showed that m-Tyr impaired the STAT3/NFκB/Notch
pathway. STAT3 has recently been considered a new
autophagy regulator31. Thus, m-Tyr impact on autophagy
may be in part due to STAT3 downmodulation and in
turn blocking this pathway may impair tumor growth and
progression.
Strikingly, our results show that m-Tyr almost com-
pletely abolished the number of experimental metastases
of PCa and even spontaneous metastasis of breast cancer
experimental models. Further, in the case of m-Tyr effect
on the survival of LMM3-tumor-excised mice exhibiting
established lung metastases at the time of surgery, we
observed no tumor relapse after surgical excision and a
significant increase in the percentage of survivors for
m-Tyr-treated animals vs. control mice. These results
demonstrate that m-Tyr not only inhibits the implantation
of new metastases of mice and human derived xenografts,
but also is able to impair growth of cells from the primary
tumor that may have remained post surgery. Potential
toxic side effect analysis associated with a m-Tyr periodic
administration revealed neither histologic nor cytologic
alterations, even when organs with high rate of renewal
were studied. Leukocyte subpopulations in both the
draining lymph nodes and the spleen remain unchanged
and neither the humoral nor the cellular immune
responses displayed significant changes nor any alteration
in different functional patterns in m-Tyr-treated mice.
Recently2, we have suggested that the apparent lack of
inhibitory effect of m-Tyr on normal proliferating tissues
might be explained by assuming that these tissues display
—as primary tumors do—a content of Phe high enough to
counteract the inhibitory effects produced by m-Tyr.
Up to date, there is no evidence pointing to m-Tyr
cytotoxicity in humans. Fell et al.32 reported on the
metabolism of m-Tyr in man. Oral doses of m-Tyr (5 mg/
kg) were given to adults and the amino acid blood levels
measured at intervals following the load. The majority of
the load was metabolized to m-hydroxyphenylacetic acid,
m-hydroxymandelic acid, and 3,4-dihydroxyphenylacetic
acid detected in urine samples. No detectable toxic side
effects were observed.
Our data suggest that, for therapeutic purposes, m-Tyr
has many attractive features, exerting its anti-metastatic
effect at low concentrations with no detectable toxic side
effects. Delivery of this biologically active metabolite may
boost the therapeutic efficacy of the current treatment of
cancer metastasis, specifically by controlling the outburst
of micrometastases following removal of a primary tumor,
or other stressors that might trigger the escape of
metastases from dormancy.
Materials and methods
Cell culture, treatments, reagents, and antibodies
PC3, Calu6, and KB cells were obtained from the
American Type Culture Collection (Manassas, VA, USA)
and were routinely cultured in RPMI 1640 (Invitrogen,
Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (FBS).
The mammary carcinoma cell lines C7HI and LMM3,
were kindly provided by Dr. C. Lanari (Instituto de Bio-
logía y Medicina Experimental, Buenos Aires, Argentina,
IBYME) and Dr. L. Colombo (Instituto Ángel Roffo,
Buenos Aires, Argentina), respectively. The 4T1 cell line
was provided by Dr. N. Zwirner (IBYME). m-Tyrosine (m-
Tyr) and phenylalanine (Phe) was obtained from Sigma-
Aldrich (San Luis, MO, USA). For treatments, cells were
incubated 24 h in RPMI media containing 10% FBS and
then were exposed to meta-tyrosine (m-Tyr) or phenyla-
lanine (Phe) (100 and 150 μg/ml, 24 h).
Polyclonal anti-STAT3 antibody was purchased from
Stressgen Biotechnologies Corp. (San Diego, CA). Anti-β-
Actin antibody was purchased from Sigma-Aldrich (Gil-
lingham, Dorset, UK). Anti-mouse and anti-rabbit sec-
ondary antibodies conjugated with horseradish peroxidase
(HRP) were from Amersham Ltd. (Freiberg, Germany).
Secondary antibodies conjugated with Alexa Fluor 488 or
Alexa Fluor 555 were from Molecular Probes and
Invitrogen.
Animals
Eight to 10-week-old male athymic (nu/nu) each
weighing at least 20 g, were purchased from CONEA
(Comisión Nacional de Energía Atómica/Centro Atómico
Ezeiza. Aplicaciones Tecnológicas y Agropecuarias/Bio-
terio, Buenos Aires, Argentina). BALB/c mice, 3–5-
month-old were obtained from the animal core facility at
IMEX-CONICET. Mice were used in accordance with the
“Guidelines for the Welfare of Animals in Experimental
Neoplasia” (UK Coordinating Committee on Cancer
Research) and the NIH Guide and Use of Laboratory
Animals. Protocol number 025/23016 approved by the
Institutional Committee for the Care of Laboratory Ani-
mals (CICUAL), Institute of Experimental Medicine,
CONICET.
Concomitant resistance experiments
Eight to 10-week-old male athymic (nu/nu) mice were
randomized into two groups. Human PCa cells were
injected s.c. in the right flank of the experimental group
(primary tumor-bearing mice) and, at selected times (7,
14, or 21 days) after tumor inoculation—when PC tumor
volumes were 101± 17, 317± 42, or 317± 42mm3 (mean
± S.E.), respectively—a secondary tumor implant was
carried out in the left flank. Control mice only received
the tumor implant in the left flank. Body weight and
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tumor growth were measured every 2 days starting at
8 days after inoculation when tumors became palpable
under the skin. Their volumes were calculated using the
formula 0.4 (a× b2), where a and b represent the larger
and smaller tumor diameters, respectively10.
In experiments where m-Tyr and Phe, animals were
randomly assigned into four groups: control; experimental
(CR); Phe and m-Tyr. Tumor cells (5× 106) were s.c.
inoculated (first challenge) in the right flank of animals of
the CR and Phe groups. A total of 3× 106 cells were
inoculated in the left flank of the animals of all groups
14 days after the first challenge. Twenty-four hours later,
both, Phe andm-Tyr groups were injected in the same site
with Phe or m-Tyr (0.2 ml of 500mg/ml) respectively, for
15 days on a daily basis. Tumor growth was measured
every 2 days starting 8 days after inoculation when the
tumors were palpable. Their volumes were calculated as
described above.
The generation of Calu-6 and KB experimental tumors
is described in Supplemental materials and methods.
Experimental and spontaneous metastasis
Experimental metastases of human tumor cells
For experimental PCa metastasis, nude mice (n= 9)
were i.v. challenged with 2× 106 PC3 tumor cells, and
were subsequently injected withm-Tyr or saline on a daily
basis (i.v. administration; 67 mg/kg/day). Animals were
killed 20–25 days after tumor cell inoculation and eval-
uated for pulmonary metastases or left to assess survival.
All experiments were done in triplicates.
Spontaneous metastases in tumor-bearing mice
For the analysis of the growth of spontaneous metas-
tasis, the highly metastatic murine mammary carcinomas
4T1, C7HI, and LMM3 were used. In the case of C7HI,
BALB/c mice were s.c. injected with 2× 105 cells. Forty
days later, mice were divided in three groups that
received, between days 40 and 60, a daily i.v. injection of
of m-Tyr (67mg/kg, n= 18) or saline solution (control,
n= 20). A third group (n= 10) was killed at day 40 to
evaluate the number of metastases at the onset of treat-
ment. At day 60, all mice were killed and lung and hepatic
metastases were counted. All experiments were done in
triplicates.
For LMM3 tumors, BALB/c mice were s.c. injected with
2× 105 cells. Twenty-five days later, animals were divided
in three groups that received, between 25 and 45 days, a
daily i.v. injection of m-Tyr (67 mg/kg, n= 7, respectively)
or saline (n= 15). A third group (n= 10) was killed at day
25 to evaluate the number of metastases at the onset of
treatment. At day 45, all treated and control mice were
euthanized and metastases. All experiments were done in
triplicates.
For 4T1 tumors, BALB/c mice were s.c. injected with
2× 105 cells. Twenty-five days later animals were divided
into two groups that received, between 25 and 45 days, a
daily i.v. injection of m-Tyr (67 mg/kg; n= 8) or saline (n
= 9). A third group (n= 4) was killed at day 25 to evaluate
the number of metastases at the onset of treatment. At
day 45, all treated and control mice were killed and
metastases counted. All experiments were done in
triplicates.
Spontaneous metastases after surgical extirpation of the
primary tumor
BALB/c mice (n= 22) were inoculated s.c. with 2× 105
LMM3 cells. Twenty-five days later, tumors were surgi-
cally removed from 18 tumor-bearing mice; the
remaining six animals were killed to evaluate the number
of lung metastases at the time of surgery. Lung metas-
tases were counted as described in ref. 33. Then, the
tumor-excised mice were divided into two groups. One
group (n= 8) received, for the following consecutive
35 days, a daily i.v. injection of m-Tyr (67 mg/kg). The
other group (n= 8) received saline. All experiments were
done in triplicates.
Histopathologic studies
The highest dose of m-Tyr (67 mg/kg) used in experi-
ments was daily administered by the i.v. route for 45 days
in BALB/c mice. At day 45, a sample of mice was
euthanized and the following organs—skin, liver, kidney,
spleen, lung, bone marrow, small and large intestine—
were investigated histopathologically. Samples were fixed
as previously reported7.
Luciferase assay
PC3 cells were seeded on 12-well plates (1.2× 105 cells
per well) and transfected with a NFκB—responsive luci-
ferase reporter construct (2 µg) and/or Ikbss expression
vector (2 µg) as a negative control using polietilenimine
(Sigma-Aldrich, UK). Cells were treated with m-Tyr
(150 µg/ml, 24 h) and/or Phe (150 µg/ml, 24 h). The luci-
ferase assay system (Promega, Madison, WI) was used to
measure luciferase activity in a Glomax luminometer
(Promega). Transfections were performed in triplicate and
each experiment was repeated at least three times. Data
were normalized to total protein determined by Bradford
assay.
Immunofluorescence experiments and quantitative
microscopy
Cells were seeded in 12-well plate at a density of 1× 105
cells per well on coverslips overnight. Cells were treated
with m-Tyr (150 μg/ml; 24 h), m-Tyr+ Phe (150 μg/ml;
24 h) or vehicle, fixed in ice-cold methanol, permeabilized
for 10min with 0.5% Triton X-100/phosphate-buffered
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saline (PBS), washed twice with PBS and then blocked
with 5% bovine serum albumin (BSA) in PBS. Cells were
incubated overnight with an anti-STAT3 antibody diluted
1:200 in 3% PBS and 0.1% BSA. Cells were washed with
PBS and incubated with fluorescent secondary antibodies
Alexa 647 (1:3000) for 2 h. Negative controls were carried
out using PBS instead of primary antibodies. Cells were
washed, mounted in FluorSave Reagent (Merck Milli-
pore), and imaged by confocal laser scanning microscopy
with an Olympus Fluoview FV 1000 microscope (and its
software). An Olympus water immersion ×60 objective
(1.20 N.A. UPLAN APO) objective was used. Samples
were imaged at room temperature. Wide field microscopy
was carried on using an Olympus IX71 microscope with
an Olympus UApo water immersion ×40 objective (1.15
N.A.), a mercury arc lamp excitation, and suitable filters.
Camera: Hamamatsu Orca CCD C4742-95. Samples were
imaged at room temperature.
Image processing for presentation
Confocal and wide field microscope images were pro-
cessed for presentation using ImageJ software. Back-
ground of each channel was subtracted and in some cases
a median filter (radius: 1 pixel) was applied only for
presentation
RNA isolation and RT-qPCR
Total RNA was isolated with the RNeasy Mini Kit (Qia-
gen). Complementary DNAs (cDNAs) were synthesized
with RevertAidTM Premium First Strand cDNA Synthesis
Kit (Fermentas) and used for real-time PCR amplification
with Taq DNA Polymerase (Invitrogen) in a DNA Engine
Opticon (MJ Research). Each PCR was performed in tri-
plicate and three biological independent experiments were
performed. Primers were designed to amplify a 100 bp
region present in the fully mature RNA species of Survivin
(Fw: 5′-GGAGCCAGATGACGACCCCA-3′ and Rv: 5′-
AGCGCAACCGGACGAATGCT-3′), Hes (Fw: 5′-GTGA
AGCACCTCCGGAAC-3′ and Rv: 5′-CGTTCATGCACTC
GCTGA-3′), Ki67 (Fw: 5′-CCAGCACGTCGTGTCTCAA-
GAT-3′ and Rv: 5′-ACACTGTCTTTTGAGTCATCTGCG
G-3′), STAT3 (Fw: 5′-TCGCAGCCGAGGGAACAAG-3′
and Rv: 5′-GCCATCCTGCTAAAATCAGGGG-3′), ACTB
(Fw: 5′-CGGTTGGCCTTAGGGTTCAGGGGGG-3′ and
Rv 5′-GTGGGCCGCTCTAGGCACCA-3′), and GAPDH
(Fw: 5′-CAGTCAGCCGCATCTTCTTTTG-3′ and Rv: 5′-
ACCAGAGTTAAAAGCAGCCCT-3′). Data were analyzed
by Opticon-3 software and normalized to β-actin or
GAPDH. Errors were calculated as in ref. 34.
Cell viability
Cell viability was assayed by MTS (Cell Titer 96 wells
aqueous non-radioactive Cell proliferation assay, Pro-
mega) following the manufacturer’s instructions. Each
sample was done in triplicate in five independent
experiments.
Cell cycle analysis
PC3 stable cell lines were treated with m-Tyr or Phe
(150 μg/ml; 24 h), m-Tyr+ Phe (150 μg/ml; 24 h) or
vehicle, and then stained with propidium iodide (PI) and
analyzed by fluorescence-activated cell sorting (FACS).
After 24 h exposure of the PC3 cell line to the com-
pounds, cells were collected by trypsinization and gently
pelleted by centrifugation at 3000 r.p.m. for
3 min. Cells were resuspended in cold PBS and cen-
trifuged again (3000 r.p.m. for 3 min). Pellets were trans-
ferred dropwise to 1 ml of 70% (v/v) ethanol, allowed to
fix for 2 h at 4 °C, and kept on ice. The ethanol-suspended
cells were collected, washed, and resuspended in 1ml PBS
containing DNase-free RNase A (0.2 mg/ml), Triton
X-100 (0.1% v/v), and PI (0.02 mg/ml). Each sample was
then incubated at 37 °C for 15min before cell cycle ana-
lysis with a BD flow cytometer and FlowJo 7.6.2 software.
[3H]-thymidine uptake assay
A total of 3× 105 tumor cells in 0.1ml of medium were
cultured with 0.1ml of several twofold dilutions of serum
and 1mCi per ml of [3H]-thymidine (Dupont NEN
Research Products) as described6. After 18 h, radioactivity
incorporated into the cells was determined in a β counter
(Beckman). The titer of growth-inhibitory activity was
defined as the reciprocal of the serum dilution, producing
50% inhibition of [3H]-thymidine uptake by tumor cells as
compared with [3H]-thymidine uptake of tumor cells
incubated with medium only and expressed as growth-
inhibitory units 50 by ml (GIU50 per ml). Results are
expressed as mean± S.E.M. of three samples of normal
serum, three samples of serum from mice bearing large
PC3 tumors (1700mm3 approximately), and three samples
of serum from mice bearing small PC3 tumors (500mm3
approximately). Each dilution of each serum was assayed
in triplicate. *P< 0.05; ***P< 0.001 significant difference.
Serum and tyrosine purification
Serum was prepared as described in refs. 6,35. Serum was
then subjected to dialysis using a dialysis membrane with a
1 KD cutoff (width 2.5 cm) for 48 h. The dialyzable frac-
tions were lyophilized and resuspended in a mixture of
water:methanol:trifluoroacetic (87:12:1) for tyrosine deter-
mination. p-tyrosine (p-tyr), m-Tyrosine (m-tyr), and o-
tyrosine (o-tyr) determinations in the dialyzable fractions
from normal serum as well as serum from mice bearing
PC3 or Calu6 tumors were carried out using an HPLC.
Methodology is previously described in ref. 10. Briefly
p-Tyr, m-Tyr, and o-Tyr separation was performed in a
C-18 Zorbax column (Agilent Santa Clara, CA, 7.5mm×
4.6mm i.d., 5 μm particle size). The mobile phase consisted
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in a mixture of water:methanol:trifluoroacetic (87:12:1), the
flow rate was set at 0.5ml/min, and the UV detection was
performed at 280 nm. The retention times for p-Tyr,
m-Tyr, and o-Tyr were: 2.12min; 2.55min; 3.34min,
respectively. Standards for p-Tyr, m-Tyr, and o-Tyr
purchased from Sigma, Argentina, were used.
Western blot
Processing of LC3 protein into LC3-II, the phagophore-
and autophagosome-associated form was assayed. After 24 h
of m-Tyr and or m-Tyr/Phe stimulation, cells were washed
with PBS and protein extracts from fractions were obtained.
Protein concentration was determined using the bicincho-
ninic acid protein assay kit from (Sigma-Aldrich, UK).
Western blotting was performed by standard methods using
10% polyacrylamide gels. Each nitrocellulose membrane was
blotted with antibodies to LC3 (Cell Signalling Technology,
2775) and B-actin (Sigma). Bound antibodies were detected
with horseradish peroxidase-conjugated antibody (Bio-Rad,
anti-rabbit 170-6515, anti-mouse 170-6516) using Amer-
sham ECL PLUS reagent (GE Healthcare, RPN2106). Images
were obtained with an Intelligent Dark Box (Fujifilm
LAS1000, Tokyo, Japan) and analyzed with ImageJ Analysis
software. The intensity of each band was expressed as arbi-
trary units (A.U.).
Statistical analysis
Results are shown as mean± S.E.M. unless otherwise is
stated. The Student’s t test, Mann–Whitney U-test, and
Kaplan–Meier estimator for survival curves were used.
Differences were considered significant when P< 0.05.
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